oral regimen
Adding ixazomib to pomalidomide and dexamethasone improved progression-free survival rates...
Three-year follow-up data from the CAPTIVATE trial were presented at the 2022 ASCO Annual Meeting.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.